GALECTIN THERAPEUTICS INC. Increase (Decrease) in Other Noncurrent Liabilities
GALECTIN THERAPEUTICS INC. (GALT) reported Increase (Decrease) in Other Noncurrent Liabilities of -$6.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2016-03-15
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2013-12-31 was -$1.00K.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2013-09-30 was -$4.00K.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2013-06-30 was $0.00.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2013-03-31 was -$1.00K.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for fiscal 2013 was -$6.00K, a 200.00% decline from fiscal 2012.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for fiscal 2012 was $6.00K.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for fiscal 2011 was -$12.00K.
- GALECTIN THERAPEUTICS INC. increase (decrease) in other noncurrent liabilities for fiscal 2010 was -$292.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month | Increase (Decrease) in Other Noncurrent Liabilities 132 month | Increase (Decrease) in Other Noncurrent Liabilities 150 month | Increase (Decrease) in Other Noncurrent Liabilities 153 month | Increase (Decrease) in Other Noncurrent Liabilities 156 month | Increase (Decrease) in Other Noncurrent Liabilities 159 month |
|---|---|---|---|---|---|---|---|---|---|
| 2013-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$5.00K derived: sum of 2 quarters · filed 2016-03-15 | -$5.00K derived: sum of 3 quarters · filed 2016-03-15 | -$6.00K 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$4.00K derived: sum of 2 quarters · filed 2014-11-10 | -$5.00K 10-Q · filed 2014-11-10 | $1.00K 10-Q · filed 2013-11-12 | |||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$1.00K 10-Q · filed 2014-08-07 | $5.00K 10-Q · filed 2013-08-14 | ||||||
| 2013-03-31 | -$1.00K 10-Q · filed 2014-05-13 | $5.00K 10-Q · filed 2013-05-10 | |||||||
| 2012-12-31 | $6.00K 10-K · filed 2015-03-18 | $6.00K 10-K · filed 2013-03-29 | |||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | -$3.00K derived: sum of 2 quarters · filed 2013-03-29 | -$7.00K derived: sum of 3 quarters · filed 2013-03-29 | -$12.00K 10-K · filed 2013-03-29 | |||||
| 2011-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$7.00K derived: sum of 2 quarters · filed 2012-11-09 | -$12.00K 10-Q · filed 2012-11-09 | -$14.00K derived: sum of 4 quarters · filed 2012-11-09 | |||||
| 2011-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-10 | -$9.00K 10-Q · filed 2012-08-10 | -$11.00K derived: sum of 3 quarters · filed 2012-08-10 | -$15.00K derived: sum of 4 quarters · filed 2012-08-10 | $3.00K 10-Q · filed 2011-08-12 | ||||
| 2011-03-31 | -$5.00K 10-Q · filed 2012-05-11 | -$7.00K derived: sum of 2 quarters · filed 2012-05-11 | -$11.00K derived: sum of 3 quarters · filed 2012-05-11 | ||||||
| 2010-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | -$6.00K derived: sum of 2 quarters · filed 2012-03-30 | -$292.00K 10-K · filed 2012-03-30 | ||||||
| 2010-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | -$290.00K 10-Q · filed 2011-11-10 | |||||||
| 2010-06-30 | -$286.00K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |